Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation

Journal of the American Academy of Dermatology

Volumn 54, Issue 6, 2006, Pages 1083-1088

  High, Whitney A ^a   Pandya, Amit G ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEVICE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; HYPOPIGMENTATION; MALE; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; SEBORRHEIC DERMATITIS; SKIN PIGMENTATION;

ADULT; AFRICAN AMERICANS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, SEBORRHEIC; DOSAGE FORMS; FEMALE; HUMANS; HYPOPIGMENTATION; MALE; MIDDLE AGED; PILOT PROJECTS; TACROLIMUS;

EID: 33646536099     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.01.011     Document Type: Article

References (35)

1. Plewig G., and Jansen T. Seborrheic dermatitis. In: Freedberg I.M., Eisen A.Z., Wolff K., Austen K.F., Goldsmith L.A., and Katz S. (Eds). Fitzpatrick's dermatology in general medicine. 6th ed. (2003), McGraw-Hill, New York 1198-1204
2. Mathes B.M., and Douglass M.C. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 13 (1985) 947-951
3. Fischer M., Gemende I., Marsch W.C., and Fischer P.A. Skin function and skin disorders in Parkinson's disease. J Neural Transm 108 (2001) 205-213
4. Nakabayashi A., Sei Y., and Guillot J. Identification of Malassezia species isolated from patients with seborrheic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 38 (2000) 337-341
5. Pechere M., Krischer J., Remondat C., Bertrand C., Trellu L., and Saurat J.H. Malassezia spp carriage in patients with seborrheic dermatitis. J Dermatol 26 (1999) 558-561
6. Bergbrant I.M. Seborrheic dermatitis and Pityrosporum (Malassezia) yeasts. Curr Top Med Mycol 6 (1995) 95-112
7. Parry M.E., and Sharpe G.R. Seborrheic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 139 (1998) 254-263
8. Gupta A.K., Kohli Y., Summerbell R.C., and Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 39 (2001) 243-251
9. Watanabe S., Kano R., Sato H., Nakamura Y., and Hasegawa A. The effects of Malassezia yeast on cytokine production by human keratinocytes. J Invest Dermatol 116 (2001) 769-773
10. Stratigos J.D., Antoniou C., Katsambas A., Bohler K., Fritsch P., Schmolz A., et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. J Am Acad Dermatol 19 (1988) 850-853
11. Katsambas A., Antoniou C., Frangouli, Averinou G., Michailidis D., and Stratigos J. A double-blind trial of treatment of seborrheic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br J Dermatol 121 (1989) 353-357
12. Skinner R.B., Noah P.W., Taylor R.M., Zanolli M.D., West S., Guin J.D., et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 12 (1985) 852-856
13. Pierard-Franchimont C., Pierard G.E., Arrese J.E., and De Doncker P. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrheic dermatitis: clinical squamometric, and mycological assessments. Dermatology 202 (2001) 171-176
14. Bulmer A.C., and Bulmer G.S. The antifungal action of dandruff shampoo. Mycopathologia 147 (1999) 63-65
15. Efalith Multicenter Trial Group. A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 26 (1992) 452-457
16. Cuelenare C., De Bersaques J., and Kint A. Use of topical lithium succinate in the treatment of seborrheic dermatitis. Dermatology 184 (1992) 194-197
17. Davinder P., Pandhi R., Negi K.S., and Kumar B. Topical metronidazole in seborrheic dermatitis-a double blind study. Dermatology 202 (2001) 35-37
18. Dupuy P., Maurette C., Amoric J.C., and Chosidow O. Randomized, placebo-controlled, double-blind study on the clinical efficacy of ciclopiroxolamine 1% cream in the facial seborrheic dermatitis. Br J Dermatol 144 (2001) 1033-1037
19. Nakayama J. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream. Eur J Dermatol 10 (2000) 528-532
20. Gunduz K., Inanir I., and Sacar H. Efficacy of terbinafine 1% cream on seborrheic dermatitis. J Dermatol 32 (2005) 22-25
21. Braza T.J., DiCarlo J.B., Soon S.L., and McCall C.O. Tacrolimus 0.1% ointment for seborrheic dermatitis: an open-label pilot study. Br J Dermatol 148 (2003) 1242-1244
22. Crutchfield III C.E. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 70 (2002) 207-208
23. Brownell I., Quan L.T., and Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 9 (2003) 13
24. Rigopoulos D., Ioannides D., Kalogeromitros D., Gregoriou S., and Katsambas A. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis: a randomized open-label clinical trial. Br J Dermatol 151 (2004) 1071-1075
25. Kestel Jr. J.L. Hypopigmentation following the use of Cordran tape. Arch Dermatol 103 (1971) 460
26. McLaurin C.I. Annular facial dermatoses in blacks. Cutis 32 (1983) 369-370 384
27. Halder R.M. Hair and scalp disorders in blacks. Cutis 32 (1983) 378-380
28. Clarys P., Alewaeters K., Lambrecht R., and Barel A.O. Skin color measurements: comparison between three instruments: the Chromameter, the DermaSpectrometer and the Mexameter. Skin Res Technol 6 (2000) 230-238
29. Gladstone H.B., Nguyen S.L., Williams R., Ottomeyer T., Wortzman M., Jeffers M., et al. Efficacy of hydroquinone cream (USP 4%) used alone or in combination with salicylic acid peels in improving photodamage on the neck and upper chest. Dermatol Surg 26 (2000) 333-337
30. Yoshimura K., Harii K., Masuda Y., Takahashi M., Aoyama T., and Iga T. Usefulness of a narrow-band reflectance spectrophotometer in evaluating effects of depigmenting treatment. Aesthetic Plast Surg 25 (2001) 129-133
31. Hurley M.E., Guevara I.L., Gonzales R.M., and Pandya A.G. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 138 (2002) 1578-1582
32. Guevara I.L., and Pandya A.G. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 42 (2003) 966-972
33. Antille C., Saurat J.H., and Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 140 (2004) 457-460
34. Queille-Roussel C., Paul C., Duteil L., Lefebvre M.C., Rapatz G., Zagula M., et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 144 (2001) 507-513
35. Ormerod A.D. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. Br J Dermatol 153 (2005) 701-705